My work spans multiple disciplines (clinical trials, epidemiology, diagnostics, health economics, anthropology) but is unified by an unwavering drive to reduce mortality and morbidity from advanced HIV disease.

I joined the Faculty of Infectious and Tropical Diseases in 2017 and was based in Gaborone, Botswana for four years where I worked as the Lead Clinician for the AMBIsome Therapy Induction OptimisatioN (AMBITION-cm) trial. AMBITION-cm was a phase III randomised controlled trial of a single, high-dose liposomal amphotericin regimen for  HIV-associated cryptococcal meningitis and recruited patients from six sites across five countries in Southern Africa.

I returned to the UK in 2021 and following the success of the trial I am co-investigator on a number of research and non-research grants aimed at maximising the impact of the AMBITION regimen in routine care settings and applying research advances in cryptococcal meningitis to other HIV-associated fungal infections. I am co-lead of SHARE-CM, a CDC-funded implementation project which aims to improve outcomes from cryptococcal meningitis by facilitating guideline change; drug registration; drug access; training of healthcare workers and engagement with communities of people living with HIV. I am also a core member and workpackage lead of IMPRINT, an NIHR Global Health Research Group for HIV-associated fungal infections. Additionally, I am lead for social sciences of the IMPALA trial of long-acting injectable antiretroviral therapy for people with a history of poor adherence to ART and a member of the Trial Management Group for EFFECT, a trial of dual oral antifungal therapy for cryptococcal antigenaemia.